11.18.21
Arxada AG announced that it will invest CHF 20 million ($21.5 million) in its industrial biotechnological plant in Kouřim, Czech Republic, which serves the contract development and manufacturing organization (CDMO) part of its Specialty Products Solutions business.
This investment provides important infrastructure debottlenecking in connection with expanded technological options and the addition of significant formulation capacity necessitated by Arxada’s growing customer base.
“With this investment, we are strengthening our capacity to support our expanding customer base with their highly interesting and often technologically challenging projects,” Antje Gerber, president, Specialty Products Solutions, Arxada, said.
“Our site in Kouřim is an integral part of our future strategy,” added Lukas von Hippel, VP, CDMO Business Line, Arxada. “Following the implementation of our new strategy in May 2020, we have seen more customers seeking our support in their new projects. Our business development team together with our process development team in Kouřim can speed up development and shorten time to market by over a year in some cases.”
This investment provides important infrastructure debottlenecking in connection with expanded technological options and the addition of significant formulation capacity necessitated by Arxada’s growing customer base.
“With this investment, we are strengthening our capacity to support our expanding customer base with their highly interesting and often technologically challenging projects,” Antje Gerber, president, Specialty Products Solutions, Arxada, said.
“Our site in Kouřim is an integral part of our future strategy,” added Lukas von Hippel, VP, CDMO Business Line, Arxada. “Following the implementation of our new strategy in May 2020, we have seen more customers seeking our support in their new projects. Our business development team together with our process development team in Kouřim can speed up development and shorten time to market by over a year in some cases.”